OPKO Health, Inc. (OPK.MX)
- Previous Close
21.50 - Open
0.00 - Bid --
- Ask 25.00 x 200
- Day's Range
21.50 - 21.50 - 52 Week Range
15.87 - 30.00 - Volume
0 - Avg. Volume
109 - Market Cap (intraday)
14.985B - Beta (5Y Monthly) 1.84
- PE Ratio (TTM)
-- - EPS (TTM)
-4.27 - Earnings Date May 1, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
www.opko.com3,930
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: OPK.MX
Performance Overview: OPK.MX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OPK.MX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OPK.MX
Valuation Measures
Market Cap
14.54B
Enterprise Value
18.49B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.09
Price/Book (mrq)
0.63
Enterprise Value/Revenue
21.41
Enterprise Value/EBITDA
-282.15
Financial Highlights
Profitability and Income Statement
Profit Margin
-21.87%
Return on Assets (ttm)
-4.73%
Return on Equity (ttm)
-12.80%
Revenue (ttm)
863.49M
Net Income Avi to Common (ttm)
-188.86M
Diluted EPS (ttm)
-4.27
Balance Sheet and Cash Flow
Total Cash (mrq)
95.88M
Total Debt/Equity (mrq)
23.51%
Levered Free Cash Flow (ttm)
16.65M
Company Insights: OPK.MX
OPK.MX does not have Company Insights